Longer treatment time and slower ultrafiltration in hemodialysis: Associations with reduced mortality in the DOPPS

被引:421
作者
Saran, R
Bragg-Gresham, JL
Levin, NW
Twardowski, ZJ
Wizemann, V
Saito, A
Kimata, N
Gillespie, BW
Combe, C
Bommer, J
Akiba, T
Mapes, DL
Young, EW
Port, FK
机构
[1] Univ Michigan, Kidney Epidemiol & Cost Ctr, Div Nephrol, Ann Arbor, MI 48103 USA
[2] Univ Renal Res & Educ Assoc, Ann Arbor, MI USA
[3] Renal Res Inst, New York, NY USA
[4] Univ Missouri, Dept Med, Div Nephrol, Columbia, MO USA
[5] Georg Haas Dialysezentrum, Giessen, Germany
[6] Tokai Univ, Sch Med, Kanagawa 2591100, Japan
[7] Tokyo Womens Med Univ, Kidney Ctr, Div Blood Purificat, Tokyo, Japan
[8] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA
[9] Ctr Hosp Univ Boredeaux, Dept Nephrol, Bordeaux, France
[10] Univ Victor Segalen Bordeaux, Bordeaux, France
[11] Heidelberg Univ, Heidelberg, Germany
[12] Dept Vet Affairs Med Ctr, Ann Arbor, MI USA
[13] Univ Michigan, Div Nephrol, Ann Arbor, MI 48109 USA
关键词
dialysis dose; dialysis session length; intradialytic hypotension; urea kinetic modeling; interdialytic weight gain; outcomes research;
D O I
10.1038/sj.ki.5000186
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Longer treatment time (TT) and slower ultrafiltration rate (UFR) are considered advantageous for hemodialysis (HD) patients. The study included 22000 HD patients from seven countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Logistic regression was used to study predictors of TT>240 min and UFR>10 ml/h/kg bodyweight. Cox regression was used for survival analyses. Statistical adjustments were made for patient demographics, comorbidities, dose of dialysis (Kt/V), and body size. Europe and Japan had significantly longer (P<0.0001) average TT than the US (232 and 244 min vs 211 in DOPPS I; 235 and 240 min vs 221 in DOPPS II). Kt/V increased concomitantly with TT in all three regions with the largest absolute difference observed in Japan. TT>240 min was independently associated with significantly lower relative risk (RR) of mortality (RR=0.81; P=0.0005). Every 30 min longer on HD was associated with a 7% lower RR of mortality (RR=0.93; P<0.0001). The RR reduction with longer TT was greatest in Japan. A synergistic interaction occurred between Kt/V and TT (P=0.007) toward mortality reduction. UFR410 ml/h/kg was associated with higher odds of intradialytic hypotension (odds ratio=1.30; P=0.045) and a higher risk of mortality (RR=1.09; P=0.02). Longer TT and higher Kt/V were independently as well as synergistically associated with lower mortality. Rapid UFR during HD was also associated with higher mortality risk. These results warrant a randomized clinical trial of longer dialysis sessions in thrice-weekly HD.
引用
收藏
页码:1222 / 1228
页数:7
相关论文
共 36 条
[1]  
Brunet P, 1996, NEPHROL DIAL TRANSPL, V11, P46
[2]  
Charra Bernard, 2002, Hemodial Int, V6, P9, DOI 10.1111/hdi.2002.6.1.9
[3]  
Charra Bernard, 2000, Hemodial Int, V4, P68, DOI 10.1111/hdi.2000.4.1.68
[4]  
DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205
[5]   Pathophysiology of dialysis hypotension: An update [J].
Daugirdas, JT .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) :S11-S17
[6]   Ultrafiltration profiling and measurement of relative blood volume as strategies to reduce hemodialysis-related side effects [J].
Donauer, J ;
Kölblin, D ;
Bek, M ;
Krause, A ;
Böhler, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (01) :115-123
[7]   Hemodialysis-induced hypotension: Impact of technologic advances [J].
Donauer, J .
SEMINARS IN DIALYSIS, 2004, 17 (05) :333-335
[8]   Effect of dialysis dose and membrane flux in maintenance hemodialysis. [J].
Eknoyan, G ;
Beck, GJ ;
Cheung, AK ;
Daugirdas, JT ;
Greene, T ;
Kusek, JW ;
Allon, M ;
Bailey, J ;
Delmez, JA ;
Depner, TA ;
Dwyer, JT ;
Levey, AS ;
Levin, NW ;
Milford, E ;
Ornt, DB ;
Rocco, MV ;
Schulman, G ;
Schwab, SJ ;
Teehan, BP ;
Toto, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (25) :2010-2019
[9]  
HARTER HR, 1983, KIDNEY INT S, V13, pS107
[10]   MORTALITY AND DURATION OF HEMODIALYSIS-TREATMENT [J].
HELD, PJ ;
LEVIN, NW ;
BOVBJERG, RR ;
PAULY, MV ;
DIAMOND, LH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (07) :871-875